Molecular Targets & Imaging Probes (MOLI7101)
Information valid for Semester 1, 2025
Course level
Postgraduate Coursework
Faculty
School
Mathematics & Physics School
Units
2
Duration
One Semester
Attendance mode
External
Class hours
General contact hours 1 Hour/ Week
Assessment methods
Examination and assignments
Course enquiries
Doctor Nick Fletcher (Semester 1, Regular, St Lucia, In person, External)
Dr Nick Fletcher
Current course offerings
Course offerings | Location | Mode | Course Profile |
Semester 1, 2025 (24/02/2025 - 21/06/2025) | St Lucia | In Person | Course Profile |
Semester 1, 2025 (24/02/2025 - 21/06/2025) | External | External | Course Profile |
Please Note: Course profiles marked as not available may still be in development.
Course description
This unit of study explores the general characteristics of molecular targets and imaging probes that are required for successful molecular imaging experiments with a focus on brain pathologies. A molecular target should: (i) be associated with a fundamental feature of a pathophysiological process, (ii) be validated by neuropathology, (iii) allow detection of disease early in its time course and (iv) lend itself to measurement as or with a biomarker that is reliable and minimally invasive. Once a molecular target for a particular disease is identified the methodology and requirements of a molecular probe suitable for imaging that target will be described. For example, optimally: (i) the imaging probe enters the brain in sufficient quantities, (ii) is stable in vivo, (iii) has moderate lipophilicity, (iv) exhibits low uptake of metabolites in brain, (v) is retained in the brain, (vi) displays high specificity and (vii) displays low non-specific binding. On completion of this unit of study, students should be able to identify molecular targets that may be useful in studying disease processes and have a clear understanding of the properties an imaging probe should possess to enable in vivo imaging of the molecular target of interest. In addition, this unit will provide the rationale for determining whether a drug is suitable for development into an imaging probe and approaches for the selection of suitable isotopes and radiolabelling methodologies for the probe and pathological process.